( 03347.hk) | 53.12 | 1.48 | 0.81% (静0.76%) | 上市时间2020-08-07股价39.82港币涨跌幅5.07%成交金额7,328.61万港币换手率0.21%市值342.86亿港币H股市值49.03亿港币总股本8.61亿H股本1.23亿每手股数100上市至今年化投资收益率-16.00%港股通持仓占H股比例46.29% (20.85亿港币2026-03-23) 累计做空占H股比例8.83% (4.57亿港币2026-03-13) | |||
| 所属三级行业生物技术 (恒生) | 市盈率 | 311.91 | 市净率 | 4.54 | 股息率 | 0.41% (静0.36%) | 恒生:医疗保健业药品及生物科技生物技术 |
| 所属指数指数纳入纳出 | |||||||
| 同股同权 | 查看历史折扣 | ||||||
| 备注 (3): | 双击编辑备注 |
泰格医药(03347) - 历史董事名单
| # | 姓名 | 职衔 | 职位 | 委任日期 | 辞任日期 |
|---|---|---|---|---|---|
| 1 | 聞增玉 | Executive Director | 2023-05-23 | -- | |
| 2 | 袁華剛 | Independent Non Executive Director | 2023-05-23 | -- | |
| 3 | 吳灝 | Executive Director | 2021-10-15 | -- | |
| 4 | 廖啟宇 | Independent Non Executive Director - A/F | 2020-04-01 | -- | |
| 5 | 楊波 | Independent Non Executive Director | 2020-04-01 | -- | |
| 6 | 鄭碧筠 | Independent Non Executive Director | 2017-06-01 | 2023-05-23 | |
| 7 | 曹曉春 | Executive Director | 2010-09-01 | -- | |
| 8 | 葉小平 | Executive Director | Chairman | 2010-09-01 | -- |
| 9 | YIN Zhuan | Executive Director | 2010-09-01 | 2023-05-23 |